Financhill
Back

Novavax 10K Form

Sell
28

NVAX
Novavax

Last Price:
8.47
Seasonality Move:
18.22%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

Receive NVAX News And Ratings

See the #1 stock for the next 7 days that we like better than NVAX

NVAX Financial Statistics

Sales & Book Value

Annual Sales: $556.38M
Cash Flow: $-146.83M
Price / Cash Flow: 0
Annual Sales: $-3.29
Price / Book: 0

Profitability

EPS (TTM): -2.29000
Net Income (TTM): $-284.86M
Gross Margin: $212.61M
Return on Equity: 0%
Return on Assets: -17.08%

Novavax Earnings Forecast

Key Novavax Financial Ratios

  • The Gross Profit Margin over the past 25 years for NVAX is 38.21%.
  • The Selling, General & Administrative Expenses for NVAX have been equal to 84.28% of Gross Profit Margin.
  • The Research & Development expenses have been 132.55% of Revenue.
  • The Interest Expense is -2.64% of Operating Income.
  • The Net Earning history of NVAX is -97.97% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 13 years.

Novavax Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: NVAX
CUSIP: 670002
Website: novavax.com

Debt

Debt-to-Equity Ratio: -0.32
Current Ratio: 0.93
Quick Ratio: 0.85

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 8.87

NVAX Technical Analysis vs Fundamental Analysis

Sell
28
Novavax (NVAX) is a Sell

Is Novavax a Buy or a Sell?

  • Novavax stock is rated a Sell
    The current Novavax [NVAX] share price is $8.47. The Score for NVAX is 28, which is 44% below its historic median score of 50, and infers higher risk than normal.